 Ofatumumab is a humanised anti-CD20 monoclonal antibody whose epitope is distinct from that of rituximab.The CD20 antigen is expressed on solely B cell lymphocytes.Compared with rituximab, ofatumumab binds more tightly to CD20 with a slower off-rate.